Rankings
▼
Calendar
REGN Q2 2025 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q2 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3.7B
+3.6% YoY
Gross Profit
$3.1B
85.6% margin
Operating Income
$1.1B
29.4% margin
Net Income
$1.4B
37.9% margin
EPS (Diluted)
$12.81
QoQ Revenue Growth
+21.4%
Cash Flow
Operating Cash Flow
$1.1B
Free Cash Flow
$968M
Stock-Based Comp.
$252M
Balance Sheet
Total Assets
$38.2B
Total Liabilities
$8.3B
Stockholders' Equity
$29.9B
Cash & Equivalents
$2.0B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.7B
$3.5B
+3.6%
Gross Profit
$3.1B
$3.1B
+2.6%
Operating Income
$1.1B
$1.1B
+0.9%
Net Income
$1.4B
$1.4B
-2.8%
Revenue Segments
Collaboration Revenue
$1.9B
51%
Product
$1.6B
44%
Product and Service, Other
$184M
5%
← FY 2025
All Quarters
Q3 2025 →